Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors.

Naour AL, Prat M, Thibault B, Mével R, Lemaitre L, Leray H, Joubert MV, Coulson K, Golzio M, Lefevre L, Mery E, Martinez A, Ferron G, Delord JP, Coste A, Couderc B.

J Mol Cell Biol. 2019 Sep 3. pii: mjz090. doi: 10.1093/jmcb/mjz090. [Epub ahead of print]

PMID:
31504643
2.

IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells.

Alaeddine M, Prat M, Poinsot V, Gouazé-Andersson V, Authier H, Meunier E, Lefèvre L, Alric C, Dardenne C, Bernad J, Alric L, Segui B, Balard P, Couderc F, Couderc B, Pipy B, Coste A.

Cancer Immunol Res. 2019 Feb;7(2):321-334. doi: 10.1158/2326-6066.CIR-18-0213. Epub 2019 Jan 4.

PMID:
30610060
3.

DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death.

Thibault B, Genre L, Le Naour A, Broca C, Mery E, Vuagniaux G, Delord JP, Wiedemann N, Couderc B.

Sci Rep. 2018 Dec 14;8(1):17862. doi: 10.1038/s41598-018-35860-z.

4.

Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.

Le Naour A, Mevel R, Thibault B, Courtais E, Chantalat E, Delord JP, Couderc B, Guillermet-Guibert J, Martinez A.

Oncotarget. 2018 Jun 5;9(43):27220-27232. doi: 10.18632/oncotarget.25513. eCollection 2018 Jun 5.

5.

Fluorescence-guided surgery for cancer patients: a proof of concept study on human xenografts in mice and spontaneous tumors in pets.

Mery E, Golzio M, Guillermet S, Lanore D, Le Naour A, Thibault B, Tilkin-Mariamé AF, Bellard E, Delord JP, Querleu D, Ferron G, Couderc B.

Oncotarget. 2017 Nov 30;8(65):109559-109574. doi: 10.18632/oncotarget.22728. eCollection 2017 Dec 12.

6.

Oxidative Stress by Monoamine Oxidase-A Impairs Transcription Factor EB Activation and Autophagosome Clearance, Leading to Cardiomyocyte Necrosis and Heart Failure.

Santin Y, Sicard P, Vigneron F, Guilbeau-Frugier C, Dutaur M, Lairez O, Couderc B, Manni D, Korolchuk VI, Lezoualc'h F, Parini A, Mialet-Perez J.

Antioxid Redox Signal. 2016 Jul 1;25(1):10-27. doi: 10.1089/ars.2015.6522. Epub 2016 Apr 22.

PMID:
26959532
7.

Endothelial cell dysfunction and cardiac hypertrophy in the STOX1 model of preeclampsia.

Ducat A, Doridot L, Calicchio R, Méhats C, Vilotte JL, Castille J, Barbaux S, Couderc B, Jacques S, Letourneur F, Buffat C, Le Grand F, Laissue P, Miralles F, Vaiman D.

Sci Rep. 2016 Jan 13;6:19196. doi: 10.1038/srep19196.

8.

Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity.

Laurent V, Guérard A, Mazerolles C, Le Gonidec S, Toulet A, Nieto L, Zaidi F, Majed B, Garandeau D, Socrier Y, Golzio M, Cadoudal T, Chaoui K, Dray C, Monsarrat B, Schiltz O, Wang YY, Couderc B, Valet P, Malavaud B, Muller C.

Nat Commun. 2016 Jan 12;7:10230. doi: 10.1038/ncomms10230.

9.

F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

Thibault B, Clement E, Zorza G, Meignan S, Delord JP, Couderc B, Bailly C, Narducci F, Vandenberghe I, Kruczynski A, Guilbaud N, Ferré P, Annereau JP.

Cancer Lett. 2016 Jan 1;370(1):10-8. doi: 10.1016/j.canlet.2015.09.006. Epub 2015 Sep 25.

PMID:
26404751
10.

SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interaction.

Pasquier J, Abu-Kaoud N, Abdesselem H, Madani A, Hoarau-Véchot J, Thawadi HA, Vidal F, Couderc B, Favre G, Rafii A.

BMC Cancer. 2015 Aug 1;15:569. doi: 10.1186/s12885-015-1556-7.

11.

LRH-1 mediates anti-inflammatory and antifungal phenotype of IL-13-activated macrophages through the PPARγ ligand synthesis.

Lefèvre L, Authier H, Stein S, Majorel C, Couderc B, Dardenne C, Eddine MA, Meunier E, Bernad J, Valentin A, Pipy B, Schoonjans K, Coste A.

Nat Commun. 2015 Apr 15;6:6801. doi: 10.1038/ncomms7801.

12.

Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α.

Baer R, Cintas C, Dufresne M, Cassant-Sourdy S, Schönhuber N, Planque L, Lulka H, Couderc B, Bousquet C, Garmy-Susini B, Vanhaesebroeck B, Pyronnet S, Saur D, Guillermet-Guibert J.

Genes Dev. 2014 Dec 1;28(23):2621-35. doi: 10.1101/gad.249409.114.

13.

Sphingosine kinase 1 expressed by endothelial colony-forming cells has a critical role in their revascularization activity.

Poitevin S, Cussac D, Leroyer AS, Albinet V, Sarlon-Bartoli G, Guillet B, Hubert L, Andrieu-Abadie N, Couderc B, Parini A, Dignat-George F, Sabatier F.

Cardiovasc Res. 2014 Jul 1;103(1):121-30. doi: 10.1093/cvr/cvu104. Epub 2014 Apr 17.

PMID:
24743591
14.

Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression.

Picaud L, Thibault B, Mery E, Ouali M, Martinez A, Delord JP, Couderc B, Ferron G.

J Ovarian Res. 2014 Apr 16;7:40. doi: 10.1186/1757-2215-7-40. eCollection 2014.

15.

Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition.

Thibault B, Castells M, Delord JP, Couderc B.

Cancer Metastasis Rev. 2014 Mar;33(1):17-39. doi: 10.1007/s10555-013-9456-2. Review.

PMID:
24357056
16.

Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation.

Castells M, Milhas D, Gandy C, Thibault B, Rafii A, Delord JP, Couderc B.

Cell Death Dis. 2013 Oct 31;4:e887. doi: 10.1038/cddis.2013.384.

17.

Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer.

Bochet L, Lehuédé C, Dauvillier S, Wang YY, Dirat B, Laurent V, Dray C, Guiet R, Maridonneau-Parini I, Le Gonidec S, Couderc B, Escourrou G, Valet P, Muller C.

Cancer Res. 2013 Sep 15;73(18):5657-68. doi: 10.1158/0008-5472.CAN-13-0530. Epub 2013 Jul 31.

18.

Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells.

Lanvin O, Monferran S, Delmas C, Couderc B, Toulas C, Cohen-Jonathan-Moyal E.

Eur J Cancer. 2013 Sep;49(13):2884-91. doi: 10.1016/j.ejca.2013.05.003. Epub 2013 Jun 6.

PMID:
23747271
19.

[The management of the metastatic disease by the surgeons].

Mery E, Golzio M, Thibault B, Ferron G, Querleu D, Delord JP, Couderc B.

Bull Cancer. 2013 Apr 1;100(4):357-62. doi: 10.1684/bdc.2013.1730. French.

PMID:
23559430
20.

Statins Reduce Melanoma Development and Metastasis through MICA Overexpression.

Pich C, Teiti I, Rochaix P, Mariamé B, Couderc B, Favre G, Tilkin-Mariamé AF.

Front Immunol. 2013 Mar 13;4:62. doi: 10.3389/fimmu.2013.00062. eCollection 2013.

21.

RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor.

Médale-Giamarchi C, Lajoie-Mazenc I, Malissein E, Meunier E, Couderc B, Bergé Y, Filleron T, Keller L, Marty C, Lacroix-Triki M, Dalenc F, Doisneau-Sixou SF, Favre G.

Breast Cancer Res. 2013 Jan 22;15(1):R6. doi: 10.1186/bcr3377.

22.

Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death.

Castells M, Thibault B, Delord JP, Couderc B.

Int J Mol Sci. 2012;13(8):9545-71. doi: 10.3390/ijms13089545. Epub 2012 Jul 30. Review.

23.

Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages.

Castells M, Thibault B, Mery E, Golzio M, Pasquet M, Hennebelle I, Bourin P, Mirshahi M, Delord JP, Querleu D, Couderc B.

Cancer Lett. 2012 Dec 29;326(1):59-68. doi: 10.1016/j.canlet.2012.07.020. Epub 2012 Jul 20.

PMID:
22824244
24.

p53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice.

Villeneuve C, Guilbeau-Frugier C, Sicard P, Lairez O, Ordener C, Duparc T, De Paulis D, Couderc B, Spreux-Varoquaux O, Tortosa F, Garnier A, Knauf C, Valet P, Borchi E, Nediani C, Gharib A, Ovize M, Delisle MB, Parini A, Mialet-Perez J.

Antioxid Redox Signal. 2013 Jan 1;18(1):5-18. doi: 10.1089/ars.2011.4373. Epub 2012 Aug 10.

25.

Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.

Cuny T, Mohamed A, Graillon T, Roche C, Defilles C, Germanetti AL, Couderc B, Figarella-Branger D, Enjalbert A, Barlier A, Saveanu A.

Mol Cell Endocrinol. 2012 May 15;355(1):106-13. doi: 10.1016/j.mce.2012.01.026. Epub 2012 Feb 14.

PMID:
22348806
26.

Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks.

Cheng Q, Barboule N, Frit P, Gomez D, Bombarde O, Couderc B, Ren GS, Salles B, Calsou P.

Nucleic Acids Res. 2011 Dec;39(22):9605-19. doi: 10.1093/nar/gkr656. Epub 2011 Aug 31.

27.

Intraoperative fluorescence imaging of peritoneal dissemination of ovarian carcinomas. A preclinical study.

Mery E, Jouve E, Guillermet S, Bourgognon M, Castells M, Golzio M, Rizo P, Delord JP, Querleu D, Couderc B.

Gynecol Oncol. 2011 Jul;122(1):155-62. doi: 10.1016/j.ygyno.2011.02.035. Epub 2011 Apr 3.

PMID:
21463889
28.

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.

Delord JP, Quideau S, Rochaix P, Caselles O, Couderc B, Hennebelle I, Courbon F, Canal P, Allal BC.

Br J Cancer. 2010 Jun 29;103(1):61-72. doi: 10.1038/sj.bjc.6605699. Epub 2010 Jun 1.

29.

A new evaluation technique for the detection of impurities in purified proteins via CE with native UV-LIF.

Rodat A, Couderc B, Feurer B, Couderc F.

Electrophoresis. 2010 Jan;31(2):396-402. doi: 10.1002/elps.200900369.

PMID:
20084633
30.

Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis.

Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J, Mirshahi M, Couderc B.

Int J Cancer. 2010 May 1;126(9):2090-101. doi: 10.1002/ijc.24886.

31.

Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1.

Bousquet E, Mazières J, Privat M, Rizzati V, Casanova A, Ledoux A, Mery E, Couderc B, Favre G, Pradines A.

Cancer Res. 2009 Aug 1;69(15):6092-9. doi: 10.1158/0008-5472.CAN-08-4147. Epub 2009 Jul 14.

32.

Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours.

Rafii A, Mirshahi P, Poupot M, Faussat AM, Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J, Bergalet J, Querleu D, Dagonnet F, Fournié JJ, Marie JP, Pujade-Lauraine E, Favre G, Soria J, Mirshahi M.

PLoS One. 2008;3(12):e3894. doi: 10.1371/journal.pone.0003894. Epub 2008 Dec 16.

33.

Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.

Acunzo J, Thirion S, Roche C, Saveanu A, Gunz G, Germanetti AL, Couderc B, Cohen R, Figarella-Branger D, Dufour H, Brue T, Enjalbert A, Barlier A.

Cancer Res. 2008 Dec 15;68(24):10163-70. doi: 10.1158/0008-5472.CAN-08-1857.

34.

Preclinical study of an ex vivo gene therapy protocol for hepatocarcinoma.

Lortal B, Gross F, Peron JM, Pénary M, Berg D, Hennebelle I, Favre G, Couderc B.

Cancer Gene Ther. 2009 Apr;16(4):329-37. doi: 10.1038/cgt.2008.88. Epub 2008 Nov 7.

PMID:
18989351
35.

In vivo restoration of RhoB expression leads to ovarian tumor regression.

Couderc B, Pradines A, Rafii A, Golzio M, Deviers A, Allal C, Berg D, Penary M, Teissie J, Favre G.

Cancer Gene Ther. 2008 Jul;15(7):456-64. doi: 10.1038/cgt.2008.12. Epub 2008 Mar 14.

PMID:
18340357
36.

Tracking in vitro and in vivo siRNA electrotransfer in tumor cells.

Paganin-Gioanni A, Bellard E, Couderc B, Teissié J, Golzio M.

J RNAi Gene Silencing. 2008 May 27;4(1):281-8.

37.

In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.

Golzio M, Mazzolini L, Ledoux A, Paganin A, Izard M, Hellaudais L, Bieth A, Pillaire MJ, Cazaux C, Hoffmann JS, Couderc B, Teissié J.

Gene Ther. 2007 May;14(9):752-9. Epub 2007 Mar 8.

PMID:
17344906
38.

In vivo imaging of tumor growth after electrochemotherapy with cisplatin.

Cemazar M, Golzio M, Escoffre JM, Couderc B, Sersa G, Teissié J.

Biochem Biophys Res Commun. 2006 Sep 29;348(3):997-1002. Epub 2006 Jul 31.

PMID:
16899227
39.

Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.

Péron JM, Bureau C, Gourdy P, Lulka H, Souque A, Calippe B, Selves J, Al Saati T, Bernad J, Cordelier P, Couderc B, Pradayrol L, Pipy B, Buscail L, Vinel JP.

Gut. 2007 Jan;56(1):107-14. Epub 2006 Aug 4.

40.

Reversible inactivation of the transcriptional function of P53 protein by farnesylation.

Couderc B, Penary M, Tohfe M, Pradines A, Casteignau A, Berg D, Favre G.

BMC Biotechnol. 2006 May 29;6:26.

41.

Lens cell targetting for gene therapy of prevention of posterior capsule opacification.

Malecaze F, Lubsen NH, Serre B, Decha A, Duboue M, Penary M, Berg D, Arnaud JD, Titeux M, Kremer EJ, Couderc B.

Gene Ther. 2006 Oct;13(19):1422-9. Epub 2006 May 25.

PMID:
16724094
42.

Prevention of posterior capsule opacification by the induction of therapeutic apoptosis of residual lens cells.

Malecaze F, Decha A, Serre B, Penary M, Duboue M, Berg D, Levade T, Lubsen NH, Kremer EJ, Couderc B.

Gene Ther. 2006 Mar;13(5):440-8.

PMID:
16251995
43.

Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors.

Douin V, Bornes S, Creancier L, Rochaix P, Favre G, Prats AC, Couderc B.

BMC Biotechnol. 2004 Jul 27;4:16.

44.

Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12.

Peron JM, Couderc B, Rochaix P, Douin-Echinard V, Asnacios A, Souque A, Voigt JJ, Buscail L, Vinel JP, Favre G.

J Gastroenterol Hepatol. 2004 Apr;19(4):388-96.

PMID:
15012775
45.

Involvement of CD70 and CD80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response.

Douin-Echinard V, Péron JM, Lauwers-Cancès V, Favre G, Couderc B.

Int Immunol. 2003 Mar;15(3):359-72.

PMID:
12618480
46.

In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.

Grangeon C, Cormary C, Douin-Echinard V, Favre G, Couderc B, Tilkin-Mariamé AF.

Cancer Gene Ther. 2002 Mar;9(3):282-8.

47.

The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.

Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B.

Cancer Gene Ther. 2000 Dec;7(12):1543-56.

48.

RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody.

Baron R, Fourcade E, Lajoie-Mazenc I, Allal C, Couderc B, Barbaras R, Favre G, Faye JC, Pradines A.

Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11626-31.

49.

RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription.

Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, Sebti SM, Lajoie-Mazenc I, Pradines A.

J Biol Chem. 2000 Oct 6;275(40):31001-8.

50.

The management of adult aggressive non-Hodgkin's lymphomas.

Couderc B, Dujols JP, Mokhtari F, Norkowski JL, Slawinski JC, Schlaifer D.

Crit Rev Oncol Hematol. 2000 Jul;35(1):33-48. Review.

PMID:
10863150

Supplemental Content

Loading ...
Support Center